- Get in Touch with Us
Last Updated: Apr 25, 2025 | Study Period:
UAE BIOPSY DEVICES FILMS MARKET
KEY FINDINGS
The UAE biopsy devices market is characterised by steady growth, driven by increasing cancer cases and a robust healthcare infrastructure. The market encompasses various products, such as biopsy guns, needles, vacuum-assisted devices, and the emerging liquid biopsy techniques. Liquid biopsy is becoming a key focus due to its ability to detect cancer early with minimal invasiveness, using blood samples to analyse circulating tumour cells (CTCs) and cell-free DNA (cfDNA).
End-users in the UAE biopsy devices market primarily include hospitals, diagnostic centres, and research institutions, with hospitals accounting for the largest share due to the high volume of procedures conducted. The market is also segmented based on application, covering diagnostics for various cancers (e.g., lung, breast, prostate) and therapeutic monitoring.
Despite challenges related to the cost of advanced devices and regulatory hurdles, the UAE's commitment to expanding its healthcare infrastructure and the increasing preference for early, accurate cancer diagnosis are expected to drive market growth. The governmentâs focus on healthcare improvement and medical innovation, combined with the private sector's involvement, is likely to create opportunities for further advancements in biopsy technologies.
The market is expected to continue expanding, especially with the growing adoption of minimally invasive techniques, technological advancements, and increased awareness of the importance of early cancer detection.
A biopsy is a medical procedure in which a small sample of tissue is removed from the body for analysis, typically to diagnose diseases like cancer. Biopsy devices are essential tools in this process, enabling physicians to collect tissue samples with precision. The UAE biopsy devices market has gained prominence due to increasing healthcare needs, particularly in the diagnosis and management of cancer, which remains a leading cause of death globally and in the UAE.
The UAE employs a variety of biopsy techniques to diagnose cancer. Needle biopsy, including fine needle aspiration and core needle biopsy, is frequently used for cancers like breast, prostate, and lung. Vacuum-assisted biopsy is particularly popular for breast cancer detection due to its ability to obtain large tissue samples with precision.
Liquid biopsy, a non-invasive method that analyses circulating tumour cells and cell-free DNA in blood, is gaining traction in the UAE. It offers quicker results without the need for surgery. While surgical biopsy remains in use for complex cases, the UAE's focus on early detection and minimally invasive procedures is evident in the growing adoption of these advanced biopsy techniques.
In the UAE, biopsy devices are primarily used for oncological diagnostics, with a focus on breast, lung, colorectal, and prostate cancers. Early-stage cancer screening, especially in womenâs health programs, is critical. Additionally, biopsy tools are also used to diagnose autoimmune diseases, inflammatory conditions, and infections within hospitals and research institutions in the UAE.
The benefits of biopsy devices in the UAE context are significant. Early detection and preventive care are crucial for improving public health, and biopsy techniques play a vital role in achieving this goal. The UAE's government initiatives to enhance healthcare have led to a focus on early cancer detection, which can result in better treatment outcomes and reduced mortality rates.
Moreover, advances in biopsy technology offer more precise results while minimising patient discomfort. This is a growing priority in the UAE's world-class healthcare facilities, where patient experience and satisfaction are paramount. Non-invasive options, such as liquid biopsy, are also gaining popularity due to their ability to provide rapid results with fewer complications. This aligns with the UAE's goals of enhancing patient care and satisfaction.
The UAE, while a leader in healthcare, faces specific challenges related to biopsy devices. The high costs of advanced technologies, such as liquid biopsy, can be a barrier to adoption in smaller clinics and remote areas. This can limit access to these innovative diagnostic tools for patients in need.
Another challenge is the need for a skilled workforce to operate these advanced biopsy devices effectively. A lack of expertise can impede the widespread use of these systems, potentially leading to suboptimal outcomes. Additionally, regulatory and coverage issues surrounding liquid biopsy can limit its use for all cancer types. This may necessitate reliance on more invasive methods for a complete diagnostic picture.
Despite these challenges, the UAE's commitment to improving healthcare and early cancer detection is evident. Addressing these issues will be crucial for ensuring that all patients have access to the latest and most effective biopsy technologies.
| Sl No | Company Name | Product Description | Analyst View |
| 1 | Qiagen | QIAamp Circulating Nucleic Acid Kit: A liquid biopsy tool for extracting circulating tumour DNA (ctDNA) from blood samples. | Liquid biopsy is gaining momentum in the UAE due to its non-invasive nature. With the country's focus on precision medicine, Qiagenâs liquid biopsy solutions fit well into the growing demand for early-stage cancer detection. |
| 2 | Hologic Inc. | Brevera Breast Biopsy System: Combines vacuum-assisted biopsy with real-time imaging. This product allows physicians to view tissue samples as they are collected. | Given the UAEâs high focus on breast cancer screening and diagnostics, Hologic's Brevera system aligns with the need for quick, accurate, and minimally invasive solutions in breast biopsy procedures. |
| 3 | Illumina | TruSight Oncology 500: A comprehensive genomic profiling solution for liquid biopsy that analyses 523 genes. | In the UAEâs push for advanced diagnostics and genomics, Illuminaâs product offers extensive tumour profiling, making it valuable for personalised oncology treatments, especially in high-end hospitals in Dubai and Abu Dhabi. |
| 4 | BD (Becton, Dickinson and Company) | BD Max System: A molecular diagnostic platform capable of supporting liquid biopsy for various cancer markers. | BDâs molecular diagnostic tools can address the UAEâs growing demand for more efficient cancer detection, especially as the country adopts a higher volume of precision medicine applications in its hospitals. |
| 5 | Roche Diagnostics | Cobas EGFR Mutation Test: Detects EGFR gene mutations in plasma using liquid biopsy. | This product is highly relevant in the UAE market, where lung cancer is a rising concern. Rocheâs Cobas system enables clinicians to detect mutations without invasive procedures, fitting well with the UAEâs advanced cancer care strategies. |
| 6 | Leica Biosystems | Aperio Digital Pathology System: Offers digital slide scanning and biopsy sample management for large healthcare institutions. | With the UAE's expanding healthcare infrastructure and focus on digitization, Leicaâs Aperio system provides hospitals and diagnostic centres with the capability to integrate AI and digital pathology for more efficient cancer diagnostics. |
By Application
By End-User
By Device Type
By Material
© 2017-2025 Mobility Foresights Pvt Ltd. All rights reserved.